Analysis Tools
growth/size/body
weight loss
(
J:110814
)
|
• mice lose ~15% body weight by day 7 of treatment, comparable to wild-type
|
immune system
|
• mice develop DSS-mediated colitis at a delayed and lower severity compared to wild-type treated mice after 7 days of treatment
|
|
• mice display an increase in B cell number in the lamina propria from 27 to 43% compared to wild-type and Ccr5-deficient mice which show a transient decrease in number at day 3 and then rebound to original values by day 7 of treatment
|
|
• a decrease in number is observed at day 3 of DSS treatment
|
|
• an increase in number is observed at day 3
|
|
• mice expression one fifth the wild-type level of Ifng in the intestinal mucosa after day 3 and 7, while Il-4 is increased 3-fold and a 9-fold increase in Il-10 over wild-type and 4-fold greater than Ccr5-deficient mice after DSS-treatment
|
|
• mice show significantly fewer intraabdominal adhesions than wild-type; the colons are less erythamatous and show less ulceration; average percentage of ulcerated tissue is less than wild-type at day 3 of treatment
|
digestive/alimentary system
|
• by day 7 of a course of dextran sodium sulfate (DSS) in drinking water, null mice develop stool diarrhea and hemoccult-positive, often bloody stool similar to wild-type; development of diarrhea and bloody stools is delayed compared to wild-type with diminished hemoccult scores on day 4 and diminished diarrhea on days 1, 3, and 4
|
|
• mice develop DSS-mediated colitis at a delayed and lower severity compared to wild-type treated mice after 7 days of treatment
|
hematopoietic system
|
• mice display an increase in B cell number in the lamina propria from 27 to 43% compared to wild-type and Ccr5-deficient mice which show a transient decrease in number at day 3 and then rebound to original values by day 7 of treatment
|
|
• a decrease in number is observed at day 3 of DSS treatment
|
|
• an increase in number is observed at day 3
|
